{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:16:51Z","timestamp":1794608211447,"version":"4.9.1"},"reference-count":142,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Glucagon-like peptide-1 (GLP-1) is a 30-amino acid intestinal insulin-stimulating factor, which is mainly secreted by L cells in the distal ileum and colon. It has various physiological functions, such as promoting insulin secretion and synthesis, stimulating \u03b2-cell proliferation, inducing islet regeneration, inhibiting \u03b2-cell apoptosis and glucagon release, delaying gastric emptying and controlling appetite, etc. It plays a role through a specific GLP-1 receptor (GLP-1R) distributed in many organs or tissues and participates in the regulation of glucose homeostasis in the body. GLP-1 receptor agonists (GLP-1RAs) has the similar physiological function of GLP-1. Because of its structural difference from natural GLP-1, it is not easy to be degraded by dipeptidyl peptidase-4 (DPP-4), thus prolonging the action time. GLP-1RAs have been recognized as a new type of hypoglycemic drugs and widely used in the treatment of type 2 diabetes mellitus (T2DM). Compared with other non-insulin hypoglycemic drugs, it can not only effectively reduce blood glucose and glycosylated hemoglobin (HbA1c), but also protect cardiovascular system, nervous system and kidney function without causing hypoglycemia and weight gain. Therefore, GLP-1RAs has good application prospects and potential for further development.<\/jats:p>","DOI":"10.3389\/fphar.2024.1483792","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:20:51Z","timestamp":1737357651000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus"],"prefix":"10.3389","volume":"15","author":[{"given":"Xu","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PeiHang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YinJiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuoHua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongYu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BiNan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZongRan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2174\/1381612826666200131143231","article-title":"Glucagon and glucagon-like peptide-1 receptors: promising therapeutic targets for an effective management of diabetes mellitus","volume":"26","author":"Abbas","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"B2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1530\/eje.0.1370643","article-title":"No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes","volume":"137","author":"Ahr\u00e9n","year":"1997","journal-title":"Eur. J. Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/diseases11010050","article-title":"The possible effect of the long-term use of glucagon-like peptide-1 receptor agonists (GLP-1RA) on Hba1c and lipid profile in type 2 diabetes mellitus: a retrospective study in KAUH, Jeddah, Saudi Arabia","volume":"11","author":"Ajabnoor","year":"2023","journal-title":"Diseases"},{"key":"B4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/ph17020199","article-title":"Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the national institutes of health all of us cohort","volume":"17","author":"Aldhaleei","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes","volume":"23","author":"Aroda","year":"2022","journal-title":"Rev. Endocr. Metabolic Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/dom.12352","article-title":"Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies","volume":"16","author":"Bak","year":"2014","journal-title":"Diabetes Obes. and Metabolism"},{"key":"B8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/302716a0","article-title":"Hamster preproglucagon contains the sequence of glucagon and two related peptides","volume":"302","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.physbeh.2012.04.004","article-title":"Modulation of taste responsiveness and food preference by obesity and weight loss","volume":"107","author":"Berthoud","year":"2012","journal-title":"Physiology and Behav."},{"key":"B10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0181880","DOI":"10.1371\/journal.pone.0181880","article-title":"DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity","volume":"12","author":"B\u00f6hm","year":"2017","journal-title":"Plos One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"33851","DOI":"10.1074\/jbc.274.48.33851","article-title":"Functional regulation of L-type calcium channels via protein kinase A-mediated phosphorylation of the beta(2) subunit","volume":"274","author":"B\u00fcnemann","year":"1999","journal-title":"J. Biol. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s001250051238","article-title":"Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells","volume":"42","author":"Buteau","year":"1999","journal-title":"Diabetologia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e34122","DOI":"10.1097\/MD.0000000000034122","article-title":"Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: a network meta-analysis","volume":"102","author":"Chen","year":"2023","journal-title":"Medicina"},{"key":"B16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/jdi.13932","article-title":"Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real\u2010world clinical practice: 36 month post\u2010marketing observational study","volume":"14","author":"Chin","year":"2023","journal-title":"J. Diabetes Investigation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1900\/rds.2011.8.369","article-title":"The alpha-cell as target for type 2 diabetes therapy","volume":"8","author":"Christensen","year":"2011","journal-title":"Rev. Diabet. Stud."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1210\/en.2007-0966","article-title":"A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release","volume":"149","author":"Chu","year":"2008","journal-title":"Endocrinology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.Jaa.0001007388.97793.41","article-title":"GLP-1 receptor agonists: a review of glycemic benefits and beyond","volume":"37","author":"Clark","year":"2024","journal-title":"JAAPA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.3390\/ijms22105303","article-title":"Mechanisms of beta-cell apoptosis in type 2 diabetes-prone situations and potential protection by GLP-1-based therapies","volume":"22","author":"Costes","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3969\/j.issn.1672-2809.2018.z1.001","article-title":"Expert consensus of combined oral hypoglycemic medication for Chinese adult type 2 diabetes","volume":"15","author":"Cse","year":"2018","journal-title":"Drug Eval."},{"key":"B22","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3760\/cma.j.cn112138-20200704-00646","article-title":"Consensus recommendations on utilizing glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus","volume":"59","author":"Cse","year":"2020","journal-title":"Chin. J. Intern. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1210\/en.2011-1795","article-title":"Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro","volume":"153","author":"Dalvi","year":"2012","journal-title":"Endocrinology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/cphy.c190025","article-title":"Glucagon\u2010like peptide\u20101: actions and influence on pancreatic hormone function","volume":"10","author":"Davis","year":"2020","journal-title":"Compr. Physiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1210\/jc.2009-1503","article-title":"Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia","volume":"95","author":"Deane","year":"2010","journal-title":"J. Clin. Endocrinol. and Metabolism"},{"key":"B26","doi-asserted-by":"publisher","first-page":"G424","DOI":"10.1152\/ajpgi.2002.282.3.G424","article-title":"Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans","volume":"282","author":"Delgado-Aros","year":"2002","journal-title":"Am. J. Physiology-Gastrointestinal Liver Physiology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cmet.2010.04.007","article-title":"GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis","volume":"11","author":"De Marinis","year":"2010","journal-title":"Cell Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","article-title":"Gut microbiome and health: mechanistic insights","volume":"71","author":"de Vos","year":"2022","journal-title":"Gut"},{"key":"B29","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol. and Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2337\/diab.47.2.159","article-title":"Glucagon-like peptides","volume":"47","author":"Drucker","year":"1998","journal-title":"Diabetes"},{"key":"B31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1210\/me.2002-0306","article-title":"Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis","volume":"17","author":"Drucker","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: from basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.7501\/j.issn.1674-6376.2020.03.037","article-title":"Advances in the study of marketed glucagon-like peptide-1 receptor agonists","volume":"43","author":"Du","year":"2020","journal-title":"Drug Eval. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/13813455.1929.11864670","article-title":"Contributions a l\u2019\u00e9tude des variations physiologiques de la s\u00e9cr\u00e9tion interne du pancr\u00e9as relations entre les s\u00e9cr\u00e9tions externe et interne du pancr\u00e9as","volume":"31","author":"Edgard","year":"2017","journal-title":"Arch. Int. Physiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1210\/jcem-24-10-1076","article-title":"Plasma insulin response to oral and intravenous glucose administration","volume":"24","author":"Elrick","year":"1964","journal-title":"J. Of Clin. Endocrinol. and Metabolism"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.2337\/db11-0227","article-title":"Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice","volume":"60","author":"Everard","year":"2011","journal-title":"Diabetes"},{"key":"B38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.metabol.2016.02.002","article-title":"Central nervous system regulation of eating: insights from human brain imaging","volume":"65","author":"Farr","year":"","journal-title":"Metabolism"},{"key":"B39","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","article-title":"GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial","volume":"59","author":"Farr","year":"","journal-title":"Diabetologia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12325-010-0110-x","article-title":"The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients","volume":"28","author":"Flint","year":"2011","journal-title":"Adv. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1476-5381.2010.01107.x","article-title":"Role of phosphodiesterase and adenylate cyclase isozymes in murine colonic glucagon\u2010like peptide 1 secreting cells","volume":"163","author":"Friedlander","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s00125-023-06060-w","article-title":"GLP-1 metabolite GLP-1(9\u201336) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion","volume":"67","author":"Gandasi","year":"2024","journal-title":"Diabetologia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3969\/j.issn.1672-7851.2013.10.002","article-title":"Expert consensus on the application of oral hypoglycemic drugs in patients with cardiovascular disease complicated with diabetes mellitus","volume":"8","author":"Gao","year":"2014","journal-title":"Diabetes World"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e3070","DOI":"10.1002\/dmrr.3070","article-title":"Glucagon\u2010like peptide\u20101 receptor agonists in type 2 diabetes treatment: are they all the same?","volume":"35","author":"Gentilella","year":"2019","journal-title":"Diabetes\/Metabolism Res. Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-019-1107-y","article-title":"Epidemiology of diabetes mellitus and cardiovascular disease","volume":"21","author":"Glovaci","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"116342","DOI":"10.1016\/j.ejmech.2024.116342","article-title":"Glucagon-like peptide-1 analogs: miracle drugs are blooming?","volume":"269","author":"Gong","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2337\/db11-1029","article-title":"Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion","volume":"61","author":"Gorboulev","year":"2012","journal-title":"Diabetes"},{"key":"B48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-physiol-021115-105439","article-title":"Enteroendocrine cells: chemosensors in the intestinal epithelium","volume":"78","author":"Gribble","year":"2016","journal-title":"Annu. Rev. Physiology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s42255-020-00327-x","article-title":"Metabolic Messengers: glucagon-like peptide 1","volume":"3","author":"Gribble","year":"2021","journal-title":"Nat. Metab."},{"key":"B50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1210\/er.2006-0007","article-title":"Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains","volume":"28","author":"Gromada","year":"2007","journal-title":"Endocr. Rev."},{"key":"B51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.euroneuro.2024.02.003","article-title":"Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis","volume":"82","author":"Guirguis","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2337\/dc15-2383","article-title":"GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes","volume":"39","author":"Halden","year":"2016","journal-title":"Diabetes Care"},{"key":"B53","doi-asserted-by":"publisher","first-page":"37446","DOI":"10.1074\/jbc.M205401200","article-title":"Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin","volume":"277","author":"H\u00e4rndahl","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B54","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1463-1326.2011.01456.x","article-title":"Metabolic impact of glucagon deficiency","volume":"13","author":"Hayashi","year":"2011","journal-title":"Diabetes, Obes. Metabolism"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1210\/endo-115-6-2176","article-title":"Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid","volume":"115","author":"Heinrich","year":"1984","journal-title":"Endocrinology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1007\/s10620-022-07519-3","article-title":"Discovery of the GI effects of GLP-1: an historical perspective","volume":"67","author":"Holst","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s00125-005-1705-7","article-title":"Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors","volume":"48","author":"Holst","year":"2005","journal-title":"Diabetologia"},{"key":"B59","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2337\/diabetes.53.1.5","article-title":"Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell","volume":"53","author":"Holz","year":"2004","journal-title":"Diabetes"},{"key":"B60","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3390\/medicina60030357","article-title":"A review and meta-analysis of the safety and efficacy of using glucagon-like peptide-1 receptor agonists","volume":"60","author":"Hu","year":"2024","journal-title":"Medicina"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1038\/emm.2013.47","article-title":"B-cell translocation gene 2 positively regulates GLP-1-stimulated insulin secretion via induction of PDX-1 in pancreatic \u03b2-cells","volume":"45","author":"Hwang","year":"2013","journal-title":"Exp. and Mol. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/1574886315999201208212356","article-title":"Efficacy and cardiovascular safety of GLP-1 receptor analogues","volume":"16","author":"Iqbal","year":"2021","journal-title":"Curr. Drug Saf."},{"key":"B63","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1463-1326.2012.01557.x","article-title":"Liraglutide: short-lived effect on gastric emptying\u2014long lasting effects on body weight","volume":"14","author":"Jelsing","year":"2012","journal-title":"Diabetes, Obes. Metabolism"},{"key":"B64","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3969\/j.issn.1006\u20106187.2022.06.002","article-title":"Evidence and expert guidance of glucagon-like peptide-1 receptor agonist weekly preparation in China","volume":"30","author":"Ji","year":"2022","journal-title":"Chin. J. Diabetes"},{"key":"B65","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.peptides.2017.12.013","article-title":"Control of insulin secretion by GLP-1","volume":"100","author":"Jones","year":"2018","journal-title":"Peptides"},{"key":"B66","doi-asserted-by":"publisher","first-page":"E122","DOI":"10.1152\/ajpendo.00073.2012","article-title":"Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance","volume":"303","author":"J\u00f8rgensen","year":"2012","journal-title":"Am. J. Physiology-Endocrinology Metabolism"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1210\/clinem\/dgz140","article-title":"GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity","volume":"105","author":"Kadouh","year":"2020","journal-title":"J. Clin. Endocrinol. and Metabolism"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s13300-020-00894-y","article-title":"A review on semaglutide: an oral glucagon-like peptide 1 receptor agonist in management of type 2 diabetes mellitus","volume":"11","author":"Kalra","year":"2020","journal-title":"Diabetes Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.3390\/ijms16036281","article-title":"Role of pancreatic transcription factors in maintenance of mature \u03b2-cell function","volume":"16","author":"Kaneto","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"171742","DOI":"10.1155\/2015\/171742","article-title":"Medicinal plants qua glucagon-like peptide-1 secretagogue via intestinal nutrient sensors","volume":"2015","author":"Kim","year":"2015","journal-title":"Evidence-Based Complementary Altern. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1172\/jci42497","article-title":"Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice","volume":"122","author":"Lamont","year":"2012","journal-title":"J. Clin. Investigation"},{"key":"B72","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/BF02064202","article-title":"Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans","volume":"40","author":"Layer","year":"1995","journal-title":"Dig. Dis. Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1006\/bbrc.2000.3763","article-title":"Expression of cAMP-regulated guanine nucleotide exchange factors in pancreatic beta-cells","volume":"278","author":"Leech","year":"2000","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s41401-021-00680-x","article-title":"Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1\/GLP1R signaling in rats","volume":"42","author":"Li","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1210\/jc.2005-2220","article-title":"Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses","volume":"91","author":"Little","year":"2006","journal-title":"J. Clin. Endocrinol. and Metabolism"},{"key":"B77","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3969\/j.issn.1006\u20436187.2022.05.001","article-title":"Consensus of Chinese experts on oral hypoglycemic drugs combined with initial insulin in the treatment of type 2 diabetes mellitus","volume":"30","author":"Liu","year":"2022","journal-title":"Chin. J. Diabetes"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.26355\/eurrev_202107_26395","article-title":"Liraglutide improves pancreatic islet \u03b2 cell apoptosis in rats with type 2 diabetes mellitus by inhibiting the IKK\u03b5\/NF-\u03baB pathway","volume":"25","author":"Liu","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1073\/pnas.80.18.5485","article-title":"Mammalian pancreatic preproglucagon contains three glucagon-related peptides","volume":"80","author":"Lopez","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B80","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/1570161117666190405165911","article-title":"The growing epidemic of diabetes mellitus","volume":"18","author":"Lovic","year":"2020","journal-title":"Curr. Vasc. Pharmacol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11892-014-0555-4","article-title":"Glucagon and type 2 diabetes: the return of the alpha cell","volume":"14","author":"Lund","year":"2014","journal-title":"Curr. Diabetes Rep."},{"key":"B82","doi-asserted-by":"publisher","first-page":"109138","DOI":"10.1016\/j.biopha.2019.109138","article-title":"Research progress in the relationship between type 2 diabetes mellitus and intestinal flora","volume":"117","author":"Ma","year":"2019","journal-title":"Biomed. and Pharmacother."},{"key":"B83","doi-asserted-by":"publisher","first-page":"52446","DOI":"10.1074\/jbc.M307612200","article-title":"Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP\/protein kinase A and phosphatidylinositol 3-kinase signaling pathways","volume":"278","author":"MacDonald","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/279530","article-title":"Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function","volume":"2011","author":"Marathe","year":"2011","journal-title":"Exp. Diabetes Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1002\/edm2.462","article-title":"Glucagon\u2010like peptide agonists: a prospective review","volume":"7","author":"Mariam","year":"2024","journal-title":"Endocrinol. Diabetes and Metabolism"},{"key":"B86","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1124\/pr.55.1.6","article-title":"International union of Pharmacology. XXXV. The glucagon receptor family","volume":"55","author":"Mayo","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"B87","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.3390\/nu15245096","article-title":"Nutritional strategies for the management of type 2 diabetes mellitus: a narrative review","volume":"15","author":"Minari","year":"2023","journal-title":"Nutrients"},{"key":"B88","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J. Clin. Investigation"},{"key":"B89","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1042\/bj0010028","article-title":"On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane","volume":"1","author":"Moore","year":"1906","journal-title":"Biochem. J."},{"key":"B91","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"B92","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J. Clin. Endocrinol. and Metabolism"},{"key":"B94","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"B95","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"","journal-title":"Mol. Metab."},{"key":"B96","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/s2213-8587(21)00113-3","article-title":"Treatment of type 2 diabetes: challenges, hopes, and anticipated successes","volume":"9","author":"Nauck","year":"","journal-title":"Lancet Diabetes and Endocrinol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"513","DOI":"10.31128\/AJGP-07-21-6057","article-title":"Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes","volume":"51","author":"Ng","year":"2022","journal-title":"Aust. J. General Pract."},{"key":"B98","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","article-title":"Gut hormone co-agonists for the treatment of obesity: from bench to bedside","volume":"5","author":"Nogueiras","year":"2023","journal-title":"Nat. Metab."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e13857","DOI":"10.1111\/apha.13857","article-title":"The highly expressed calcium\u2010insensitive synaptotagmin\u201011 and synaptotagmin\u201013 modulate insulin secretion","volume":"236","author":"Ofori","year":"2022","journal-title":"Acta Physiol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s00125-012-2585-2","article-title":"Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion","volume":"55","author":"Parker","year":"","journal-title":"Diabetologia"},{"key":"B101","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1476-5381.2011.01561.x","article-title":"Molecular mechanisms underlying bile acid\u2010stimulated glucagon\u2010like peptide\u20101 secretion","volume":"165","author":"Parker","year":"","journal-title":"Br. J. Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s11695-012-0622-3","article-title":"Metabolic and hormonal changes after laparoscopic roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial","volume":"22","author":"Peterli","year":"2012","journal-title":"Obes. Surg."},{"key":"B103","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2337\/db13-0991","article-title":"Generation of L Cells in mouse and human small intestine organoids","volume":"63","author":"Petersen","year":"2014","journal-title":"Diabetes"},{"key":"B104","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12902-022-01036-0","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials","volume":"22","author":"Qin","year":"2022","journal-title":"BMC Endocr. Disord."},{"key":"B105","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.peptides.2015.06.006","article-title":"High fat diet impairs the function of glucagon-like peptide-1 producing L-cells","volume":"77","author":"Richards","year":"2016","journal-title":"Peptides"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/db13-1440","article-title":"Identification and characterization of GLP-1 receptor\u2013expressing cells using a new transgenic mouse model","volume":"63","author":"Richards","year":"2014","journal-title":"Diabetes"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/ijo.2014.20","article-title":"Impact of high-fat feeding on basic helix\u2013loop\u2013helix transcription factors controlling enteroendocrine cell differentiation","volume":"38","author":"Sakar","year":"2014","journal-title":"Int. J. Obes."},{"key":"B108","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/gut.46.5.622","article-title":"Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans","volume":"46","author":"Schirra","year":"2000","journal-title":"Gut"},{"key":"B109","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/gut.2004.059741","article-title":"Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans","volume":"55","author":"Schirra","year":"2006","journal-title":"Gut"},{"key":"B110","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/gut.50.3.341","article-title":"Effects of glucagon-like peptide-1(7\u201336)amide on motility and sensation of the proximal stomach in humans","volume":"50","author":"Schirra","year":"2002","journal-title":"Gut"},{"key":"B111","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/jci75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J. Clin. Investigation"},{"key":"B112","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: current advancements and challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed. and Pharmacother."},{"key":"B113","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes and Metabolic Syndrome Clin. Res. and Rev."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6039\/j.issn.1001-0408.2023.11.01","article-title":"Medication guidelines for glucagon-like peptide-1 receptor agonist (2023 edition)","volume":"34","author":"Si","year":"2023","journal-title":"China Pharm."},{"key":"B115","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1365-2796.1996.377740000.x","article-title":"Diabetes mellitus and impaired pancreatic beta-cell proliferation","volume":"239","author":"Sj\u00f6holm","year":"1996","journal-title":"J. Intern. Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.cmet.2014.04.005","article-title":"The role of \u03b2 cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs","volume":"19","author":"Smith","year":"2014","journal-title":"Cell Metab."},{"key":"B117","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2337\/diabetes.49.5.741","article-title":"Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas","volume":"49","author":"Stoffers","year":"2000","journal-title":"Diabetes"},{"key":"B118","doi-asserted-by":"publisher","first-page":"174843","DOI":"10.1016\/j.ejphar.2022.174843","article-title":"Improving effect of cordycepin on insulin synthesis and secretion in normal and oxidative-damaged INS-1 cells","volume":"920","author":"Sun","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1096\/fasebj.12.12.1173","article-title":"Glucose and glucoincretin peptides synergize to induce c\u2010fos, c\u2010jun,junB,zif\u2010268, and nur\u201077gene expression in pancreatic \u03b2(INS\u20101) cells","volume":"12","author":"Susini","year":"1998","journal-title":"FASEB J."},{"key":"B120","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2337\/diab.32.1.14","article-title":"Effects of aging on the regenerative capacity of the pancreatic B-cell of the rat","volume":"32","author":"Swenne","year":"1983","journal-title":"Diabetes"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e142243","DOI":"10.1172\/jci142243","article-title":"Pharmacological treatment of hyperglycemia in type 2 diabetes","volume":"131","author":"Taylor","year":"2021","journal-title":"J. Clin. Investigation"},{"key":"B122","doi-asserted-by":"publisher","first-page":"162","DOI":"10.17305\/bjbms.2016.919","article-title":"Apoptosis in pancreatic \u03b2-islet cells in Type 2 diabetes","volume":"16","author":"Tomita","year":"2016","journal-title":"Bosnian J. Basic Med. Sci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1369\/jhc.2008.951319","article-title":"Expression of the GLP-1 receptor in mouse, rat, and human pancreas","volume":"56","author":"Tornehave","year":"2008","journal-title":"J. Histochem. and Cytochem."},{"key":"B124","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2337\/diabetes.49.4.611","article-title":"Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes","volume":"49","author":"Vella","year":"2000","journal-title":"Diabetes"},{"key":"B126","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"beta-cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg","year":"2007","journal-title":"Endocr. Rev."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1210\/endo.142.5.8128","article-title":"Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate\/protein kinase A-dependent mechanism","volume":"142","author":"Wang","year":"2001","journal-title":"Endocrinology"},{"key":"B128","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2337\/diab.38.3.338","article-title":"Glucagonlike peptide I (7-37) actions on endocrine pancreas","volume":"38","author":"Weir","year":"1989","journal-title":"Diabetes"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1556\/650.2019.31615","article-title":"A gl\u00fckagonszer\u0171 peptid-1 (GLP1) \u00e9s a gyomor-b\u00e9l rendszer. GLP1-receptor-agonist\u00e1k - t\u00fal\u00e9rt\u00e9kelt gyomor-elfelejt\u0151d\u00f6tt b\u00e9l- (\u201eileal brake) hat\u00e1s?","volume":"160","author":"Winkler","year":"2019","journal-title":"Orvosi Hetil."},{"key":"B130","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12325-022-02385-x","article-title":"Once-weekly semaglutide use in type 2 diabetes: real-world data from the SURE Netherlands observational study","volume":"40","author":"Wolffenbuttel","year":"2023","journal-title":"Adv. Ther."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1244432","DOI":"10.3389\/fendo.2023.1244432","article-title":"Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review","volume":"14","author":"Xie","year":"2023","journal-title":"Front. Endocrinol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats","volume":"48","author":"Xu","year":"1999","journal-title":"Diabetes"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1210\/me.2012-1004","article-title":"Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes","volume":"26","author":"Yang","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"Bmj"},{"key":"B135","doi-asserted-by":"publisher","first-page":"976465","DOI":"10.3389\/fendo.2022.976465","article-title":"Research progress on the mechanism of beta-cell apoptosis in type 2 diabetes mellitus","volume":"13","author":"You","year":"2022","journal-title":"Front. Endocrinol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"721","DOI":"10.12048\/j.issn.1674-229X.2024.10.001","article-title":"Consensus of medical experts on clinical application of glucagon-like peptide-1 receptor agonist (GLP-1RA)","volume":"34","author":"Zeng","year":"2024","journal-title":"Pharm. Today"},{"key":"B137","doi-asserted-by":"publisher","first-page":"e13764","DOI":"10.1111\/cpr.13764","article-title":"Terazosin, a repurposed GPR119 agonist, ameliorates mitophagy and \u03b2\u2010cell function in NAFPD by inhibiting MST1\u2010Foxo3a signalling pathway","author":"Zhang","year":"2024","journal-title":"Cell Prolif."},{"key":"B138","doi-asserted-by":"publisher","first-page":"7589","DOI":"10.3892\/mmr.2015.4355","article-title":"Protein kinase C pathway mediates the protective effects of glucagon-like peptide-1 on the apoptosis of islet \u03b2-cells","volume":"12","author":"Zhang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"B139","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1177\/15353702231214270","article-title":"Progress in the contrary effects of glucagon-like peptide-1 and chemerin on obesity development","volume":"248","author":"Zhang","year":"2023","journal-title":"Exp. Biol. Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"114817","DOI":"10.1016\/j.bcp.2021.114817","article-title":"Phytochemicals modulate pancreatic islet \u03b2 cell function through glucagon-like peptide-1-related mechanisms","volume":"197","author":"Zheng","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"481","DOI":"10.21037\/atm-22-1769","article-title":"Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of \u201cSGLT1 bridge\u201d as an indication for \u201csurgical diabetes\u201d","volume":"10","author":"Zhu","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"B143","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13287-017-0694-z","article-title":"PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration","volume":"8","author":"Zhu","year":"2017","journal-title":"Stem Cell Res. and Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1483792\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:21:05Z","timestamp":1737357665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1483792\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":142,"alternative-id":["10.3389\/fphar.2024.1483792"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1483792","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"article-number":"1483792"}}